Amycretin

Amycretin is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally.

Initial trials
On 7 March 2024, Novo Nordisk announced the results from the Phase I trial of the pill form of Amycretin showed participants lost 13.1% of their weight after 12 weeks. For comparison, clinical trials for the older drug Wegovy which was also developed by Novo Nordisk indicated weight loss of 6% after 12 weeks and 15% after 68 weeks.

Novo Nordisk Chief Executive Lars Fruergaard Jørgensen forecasts the roll-out of amycretin to be largely injectable medicines at first with oral versions being introduced later in higher-priced markets.